Logiscreen

Pfizer Inc

$26.04
Market Cap 148.07B
ROE 8.4%
Gross Margin 75.4%
Debt/Equity 0.7
Current Ratio 1.2
Revenue QoQ 5.4%
EPS QoQ -0.1%
F-Score 5

About

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific immune-engaging antibodies. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and thoracic cancers, such as lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 175 years, we have worked to make a difference for all who rely on us.

Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
19.50
vs median 33.61
P/B
1.62
vs median 2.16
ROE
0.08
vs median 0.09

Decent quality with acceptable fundamentals

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics